First Time Loading...
B

Baolingbao Biology Co Ltd
SZSE:002286

Watchlist Manager
Baolingbao Biology Co Ltd
SZSE:002286
Watchlist
Price: 6.78 CNY -1.88%
Updated: May 14, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Balance Sheet

2.7B
-4%
Assets
Growth Rates:
1 Year
-12%
3 Years
+2%
5 Years
+3%
7 Years
+38%
10 Years
+58%
675.4m
-11%
Liabilities
Growth Rates:
1 Year
-33%
3 Years
-34%
5 Years
-35%
7 Years
+58%
10 Years
+166%
2B
-1%
Equity
Growth Rates:
1 Year
-1%
3 Years
+24%
5 Years
+29%
7 Years
+32%
10 Years
+38%

Balance Sheet Decomposition
Baolingbao Biology Co Ltd

2.7B
Assets
675.4m
Liabilities
2.7B
Assets
675.4m
Liabilities
Current Assets 785.9m
Cash & Short-Term Investments 239m
Receivables 261.3m
Other Current Assets 285.6m
Non-Current Assets 1.9B
Long-Term Investments 291.2m
PP&E 1.4B
Intangibles 121.3m
Other Non-Current Assets 27.9m
Current Liabilities 576.5m
Accounts Payable 194.6m
Accrued Liabilities 32.8m
Short-Term Debt 260.3m
Other Current Liabilities 88.9m
Non-Current Liabilities 98.9m
Long-Term Debt 48.9m
Other Non-Current Liabilities 50m

Balance Sheet
Baolingbao Biology Co Ltd

Rotate your device to view
Balance Sheet
Currency: CNY
Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023
Assets
Cash & Cash Equivalents
123
274
263
156
416
416
245
407
375
239
Cash
0
0
0
0
0
0
1
407
375
239
Cash Equivalents
123
274
263
156
416
416
245
0
0
0
Short-Term Investments
270
50
50
90
0
0
0
107
0
0
Total Receivables
125
159
146
170
279
327
290
307
266
261
Accounts Receivables
90
114
127
151
192
191
207
284
234
229
Other Receivables
35
45
19
19
87
136
84
23
32
32
Inventory
131
132
153
173
221
186
216
285
335
279
Other Current Assets
9
10
11
169
11
17
257
209
19
7
Total Current Assets
658
625
623
757
927
946
1 008
1 315
996
786
PP&E Net
924
1 070
1 074
1 116
1 201
1 177
1 224
1 286
1 532
1 433
PP&E Gross
924
1 070
1 074
1 116
1 201
1 177
1 224
1 286
1 532
1 433
Accumulated Depreciation
268
320
395
397
475
567
609
710
799
916
Intangible Assets
110
133
144
140
138
135
134
129
125
121
Long-Term Investments
58
70
88
87
256
251
240
274
330
291
Other Long-Term Assets
15
16
3
6
58
10
10
24
23
28
Total Assets
1 765
N/A
1 914
+8%
1 932
+1%
2 107
+9%
2 579
+22%
2 519
-2%
2 616
+4%
3 029
+16%
3 006
-1%
2 659
-12%
Liabilities
Accounts Payable
137
179
163
171
205
175
292
252
314
195
Accrued Liabilities
8
13
19
21
26
31
30
44
39
33
Short-Term Debt
114
192
177
335
586
676
609
751
244
260
Current Portion of Long-Term Debt
0
0
0
0
0
0
0
5
91
45
Other Current Liabilities
21
19
29
23
168
16
26
67
71
43
Total Current Liabilities
281
403
388
549
985
899
956
1 120
759
576
Long-Term Debt
0
0
0
0
0
0
0
27
171
49
Deferred Income Tax
0
0
0
0
0
0
0
0
1
1
Minority Interest
0
0
3
2
2
0
0
0
0
0
Other Liabilities
36
33
36
33
53
53
60
69
71
49
Total Liabilities
317
N/A
435
+37%
426
-2%
584
+37%
1 039
+78%
952
-8%
1 016
+7%
1 216
+20%
1 002
-18%
675
-33%
Equity
Common Stock
369
369
369
369
369
369
369
372
372
371
Retained Earnings
279
309
337
357
366
391
430
610
721
745
Additional Paid In Capital
800
800
800
801
801
801
801
822
831
819
Treasury Stock
0
0
0
0
0
0
0
19
14
7
Other Equity
0
0
0
3
4
6
1
28
95
56
Total Equity
1 448
N/A
1 478
+2%
1 505
+2%
1 523
+1%
1 540
+1%
1 567
+2%
1 599
+2%
1 813
+13%
2 004
+11%
1 983
-1%
Total Liabilities & Equity
1 765
N/A
1 914
+8%
1 932
+1%
2 107
+9%
2 579
+22%
2 519
-2%
2 616
+4%
3 029
+16%
3 006
-1%
2 659
-12%
Shares Outstanding
Common Shares Outstanding
369
369
369
369
369
369
369
369
370
370

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 137,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.